Clinical

Dataset Information

0

Study on the efficacy of octreotide acetate for cancer-related bowel obstruction


ABSTRACT: Interventions: Octreotide acetate of 300 ug/day is administered primarily as a continuous subcutaneous infusion using a continuous infusion pump. Dosage is fixed at 300 ug/day until Day 4. In patients extubated by Day 4, dosage is fixed at 300 ug/day until Day 7. Primary outcome(s): Amelioration of abdominal symptoms (subjective parameters) Study Design: Single arm Non-randomized

DISEASE(S): Cancer-related Bowel Obstruction

PROVIDER: 2616030 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2023-05-10 | MSV000091910 | MassIVE
2005-09-14 | E-GEOD-3250 | biostudies-arrayexpress
| PRJNA1033353 | ENA
2022-11-08 | PXD034803 | Pride
2021-09-10 | PXD023860 | Pride
2021-03-23 | GSE115825 | GEO
| PRJNA476147 | ENA
2022-06-26 | GSE206757 | GEO
2018-04-30 | GSE80719 | GEO
| PRJEB21746 | ENA